Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects

Gene Therapy

Volumn 16, Issue 6, 2009, Pages 776-787

  Chen, C A ^a   Chang, M C ^a   Sun, W Z ^a   Chen, Y L ^a   Chiang, Y C ^a   Hsieh, C Y ^a   Chen, S M ^a   Hsiao, P N ^a   Cheng, W F ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CALRETICULIN PROTEIN E7 DNA VACCINE; DNA VACCINE; GOLD NANOPARTICLE; NAKED DNA; PROTEIN E7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; FEMALE; GENE GUN; IMMUNE RESPONSE; INJECTION SITE BURNING; LOCAL SKIN REACTION; LUNG METASTASIS; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; SKIN DEFECT; SUBCUTANEOUS TISSUE TUMOR; VACCINATION REACTION;

ANIMALS; ANTIGENS, CD11C; BIOLISTICS; BUFFERS; BURNS, CHEMICAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; DERMIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GOLD; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; LUCIFERASES; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PRESSURE; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

MUS;

EID: 67349215725     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.31     Document Type: Article

References (53)

1. Boyd D, Hung CF, Wu TC. DNA vaccines for cancer. IDrugs 2003; 6 1155-1164.
2. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415-2432.
3. Lin YL, Chen LK, Liao CL, Yeh CT, Ma SH, Chen JL et al. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol 1998; 72: 191-200.
4. Saravia NG, Hazbon MH, Osorio Y, Valderrama L, Walker J, Santrich C et al. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. Vaccine 2005; 23: 984-995.
5. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 1998; 4: 365-368.
6. Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M et al Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of ZYC101. Clin Cancer Res 2002; 8: 1028-1037.
7. Capone S, Zampaglione I, Vitelli A, Pezzanera M, Kierstead L, Burns J et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 2006; 177: 7462-7471.
8. Takamura S, Matsuo K, Takebe Y, Yasutomi Y. Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol 2005; 175: 2541-2547.
9. Hsieh CY, Chen CA, Huang CY, Chang MC, Lee CN, Su YN et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther 2007; 15: 1890-1897.
10. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61 3698-3703.
11. Glinka Y, Chang Y, Prud'homme GJ. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol Ther 2006; 14: 578-587.
12. Mannie MD, Abbott DJ. A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis. J Immunol 2007; 179: 1458-1465.
13. Encke J, Geissler M, Stremmel W, Wands JR. DNA-based immunization breaks tolerance in a hepatitis C virus transgenic mouse model. Hum Vaccin 2006; 2: 78-83.
14. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Hoglund U et al. In vivo electroporation enhances the immunogenicity of Hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 2007; 179: 4741-4753.
15. van Rooij EM, Haagmans BL, de Visser YE, de Bruin MG, Boersma W, Bianchi AT. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs. Vet Immunol Immunopathol 1998; 66: 113-126.
16. Cheng WF, Chen LK, Chen CA, Chang MC, Hsiao PN, Su YN et al. Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis. Mol Ther 2006; 13: 203-210.
17. Cheng WF, Hung CF, Lin KY, Ling M, Juang J, He L et al. CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Therapy 2003; 10: 1311-1320.
18. Molling K. Naked DNA for vaccine or therapy. J Mol Med 1997; 75 242-246.
19. Cheng WF, Hung CF, Chen CA, Lee CN, Su YN, Chai CY et al. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 2005; 23: 3864-3874.
20. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001; 61: 1080-1088.
21. Liao CW, Chen CA, Lee CN, Su YN, Chang MC, Syu MH et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005; 65: 9089-9098.
22. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166: 5733-5740.
23. Weiss RA. ONg retroviral particles in chick cell grown vaccines [comment]. J Clin Virol 1998; 11: 3-6.
24. Torres CA, Iwasaki A, Barber BH, Robinson HL. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 1997; 158: 4529-4532.
25. Gregersen JP. DNA vaccines. Naturwissenschaften 2001; 88: 504-513.
26. Morel PA, Falkner D, Plowey J, Larregina AT, Falo LD. DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 2004; 22: 447-456.
27. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478-11482.
28. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol Today 1998; 19: 89-97.
29. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo Jr LD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-1128.
30. Hung CF, Calizo R, Tsai YC, He L, Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine 2007; 25: 127-135.
31. Steele KE, Stabler K, VanderZanden L. Cutaneous DNA vaccination against Ebola virus by particle bombardment: Histopathology and alteration of CD3-positive dendritic epidermal cells. Vet Pathol 2001; 38: 203-215.
32. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 1997; 9: 271-283.
33. Ariyo OA, Atiri GI, Dixon AG, Winter S. The use of biolistic inoculation of cassava mosaic begomoviruses in screening cassava for resistance to cassava mosaic disease. J Virol Methods 2006; 137: 43-50.
34. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-678.
35. Cheng WF, Hung CF, Pai SI, Hsu KF, He L, Ling M et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J Biomed Sci 2002; 9: 675-687.
36. Tanigawa K, Yu H, Sun R, Nickoloff BJ, Chang AE. Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immunother 2000; 48: 635-643.
37. Hartikka J, Bozoukova V, Jones D, Mahajan R, Wloch MK, Sawdey M et al Sodium phosphate enhances plasmid DNA expression in vivo. Gene Therapy 2000; 7: 1171-1182.
38. Li ZS, Zhao Y, Rea PA. Magnesium Adenosine 5[prime]-Triphosphate-Energized Transport of Glutathione-S-Conjugates by Plant Vacuolar Membrane Vesicles. Plant Physiol 1995; 107: 1257-1268.
39. Shi SR, Cote RJ, Hawes D, Thu S, Shi Y, Young LL et al. Calcium-induced modification of protein conformation demonstrated by immunohistochemistry: What is the signal? J Histochem Cytochem 1999; 47: 463-470.
40. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998; 161: 3211-3214.
41. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994; 91: 9866-9870.
42. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008; 26: 440-448.
43. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008; 26 5210-5215.
44. Huang B, Mao CP, Peng S, Hung CF, Wu TC. RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther 2008; 19: 763-773.
45. Doria-Rose NA, Ohlen C, Polacino P, Pierce CC, Hensel MT, Kuller L et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 2003; 77: 11563-11577.
46. Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A et al. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Therapy 2008; 15: 1156-1166.
47. Curnow SJ, Scheel-Toellner D, Jenkinson W, Raza K, Durrani OM, Faint JM et al. Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol 2004; 173: 5290-5297.
48. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 2003; 31: 232-242.
49. Lin CC, Yen MC, Lin CM, Huang SS, Yang HJ, Chow NH et al. Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 2008; 10: 679-689.
50. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
51. Cheng WF, Chang MC, Sun WZ, Lee CN, Lin HW, Su YN et al. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Therapy 2008; 15: 1007-1016.
52. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Ling M et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 2001; 12: 235-252.
53. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August T, Pardoll DM et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.